| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-09-25 | MVX-ONCO-1 | head and neck squamous cell carcinoma (HNSCC) | 2 | Maxivax (Switzerland) | Cancer - Oncology |
| 2018-09-24 | AKCEA-APO(a)-LRx | patients with hyperlipoproteinemia(a) and established cardiovascular disease. | 2b | Akcea Therapeutics (USA - MA), a subsidiary of Ionis Pharmaceuticals (USA - CA) | Cardiovascular diseases - Metabolic diseases |
| 2018-09-24 | myvacTM | solid tumors | preclinical | Transgene (France) | Cancer - Oncology |
| 2018-09-21 | esketamine | treatment-resistant depression | 3 | J&J company (USA - NJ) | CNS diseases - Mental diseases |
| 2018-09-20 | THR-687 | diabetic macular edema | 1 | Onxurion (Belgium) | Ophtalmological diseases |
| 2018-09-20 | THR-317 | macular telangiectasia type 1 (MacTel 1) | 2 | Oxurion (Belgium) | Rare diseases - Ophtalmological diseases |
| 2018-09-19 | MTL-CEBPA | advanced liver cancer | 1 | Mina Therapeutics (UK) | Cancer - Oncology |
| 2018-09-15 | dupilumab | moderate-to-severe atopic dermatitis | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Autoimmune diseases - Dermatological diseases |
| 2018-09-14 | Botox® (onabotulinumtoxinA) | moderate to severe glabellar lines | Allergan (Ireland) | Aesthetic medicine | |
| 2018-09-14 | patisiran | transthyretin-mediated amyloidosis (ATTR) - familial amyloidotic polyneuropathy (FAP) | 3 | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases |
| 2018-09-13 | MOR106 | atopic dermatitis | 1 | Galapagos (Belgium) Morphosys (Germany) | Autoimmune diseases - Dermatological diseases |
| 2018-09-12 | durvalumab (Imfinzi®) and IPH5401 | solid tumors, including non small-cell lung cancer (NSCLC) with secondary resistance to prior immuno-oncology (IO) treatment and IO-naïve hepatocarcinoma (HCC) | 1-2 | Innate Pharma (France) MedImmune (USA - global biologics arm of AstraZeneca (UK) | Cancer - Oncology |
| 2018-09-10 | FPA144 (bemarituzumab) in combination with mFOLFOX6 | previously untreated, advanced gastric or gastroesophageal cancer | 1-3 | Five Prime Therapeutics (USA - CA) | Cancer - Oncology |
| 2018-09-10 | Taltz® (ixekizumab) and Tremfya® (guselkumab) | moderate to severe chronic plaque psoriasis | 4 | Eli Lilly (USA - IN) | Autoimmune diseases - Dermatological diseases |
| 2018-09-10 | sapacitabin and olaparib | BRCA mutant breast cancer | 1b-2 | Cyclacel Pharmaceuticals (USA - NJ) | Cancer - Oncology |
| 2018-09-07 | COM701 | 1 | Compugen (Israel) | Cancer - Oncology | |
| 2018-09-05 | SB-913 (adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene) | mucopolysaccharidosis type II (MPSII - Hunter's syndrome) | 1-2 | Sangamo Therapeutics (USA - CA) | Rare diseases - Genetic diseases |
| 2018-09-05 | CYAD-01 - NKR-2 (NKG2D CAR T-Cell) | colorectal cancer, ovarian Cancer, urothelial carcinoma, triple-negative breast cancer, pancreatic cancer, acute myeloid leukemia/myelodysplastic syndrome, multiple myeloma | 1b | Celyad (Belgium) | Cancer - Oncology |
| 2018-09-05 | Lenti-D™ | childhood cerebral adrenoleukodystrophy (CCALD - X-linked adrenoleukodystrophy cerebral childhood) | 2-3 | Bluebird bio (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2018-09-05 | flortaucipir F 18 (LY3303560) | 3 | Eli Lilly (USA - IN) |
